Change of Adviser

RNS Number : 9676Y

ReNeuron Group plc

14 September 2009

 



Change of Nominated Adviser and Broker

Guildford, UK, 14 September 2009: ReNeuron Group plc (the 'Company') is pleased to announce the appointment of Daniel Stewart & Company plc as Nominated Adviser and joint broker to the Company with immediate effect.  The Company is also pleased to announce that Matrix Corporate Capital LLP has been appointed as joint broker to the Company with immediate effect.

Enquiries:

Michael Hunt, Chief Executive Officer
ReNeuron	[phone]
Jonathan Birt, Susan Quigley
Financial Dynamics	[phone]
Simon Leathers
Daniel Stewart & Company plc	[phone]
Alastair Stratton, Tim Graham
Matrix Corporate Capital LLP	[phone]

About ReNeuron

ReNeuron is a leading, UK-based stem cell business. Its primary objective is the development of stem cell therapies targeting areas of significant unmet or poorly met medical need.  

ReNeuron has received regulatory and conditional ethical approvals to commence a Phase I clinical trial in the UK with its lead ReN001 stem cell therapy for disabled stroke patients. The Company is developing stem cell therapies for a number of other conditions, including peripheral arterial disease and diseases of the retina.

ReNeuron has also developed a range of stem cell lines for non-therapeutic applications - its ReNcell® products for use in academic and commercial research. The Company's ReNcell®CX and ReNcell®VM neural cell lines are marketed worldwide under license by USA-based Millipore Corporation.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as 'should', 'expects', 'estimates', 'believes' or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

 

END

 

 

APPDFLFFKKBFBBX